Review papers with raw data transparency

What the paper does (concise)

• Compiles published biomarkers of MDD and reviews which of these are reported altered during acute or convalescent COVID-19 (IL-6, sIL-6R, IL-1β, TNF-α, IFN-γ, IL-10, IL-2/sIL-2R, CRP, MCP-1, SAA1, kynurenines, low BDNF) Primary review text.
• Frames post-COVID depression within the inflammatory hypothesis of depression and suggests prospective biosignature work to predict risk.

Key evidence links cited (selected)

• IL-6: consistent MDD signal; elevated in severe COVID-19 and linked to disease severity — supports IL-6 as a convergent marker Mazza et al., cohort follow-up and meta-analytic MDD IL-6 literature Dowlati et al. meta-analysis.
• Kynurenine pathway: COVID-19 metabolomics show increased KYN/TRP ratio and altered metabolites; analogous changes are reported in MDD and associated with cognition/treatment resistance Thomas et al., metabolomics and MDD meta-analyses Ogyu et al., kynurenine meta-analysis.
• BDNF: reduced in MDD and reported lower in moderate/severe COVID-19 with partial restoration after recovery — supports growth-factor loss hypothesis as downstream effect Azoulay et al., BDNF in COVID

Critical appraisal — strengths

• Timely synthesis connecting two literatures (MDD biomarkers and COVID-19 immunometabolism) and proposing testable mechanistic cascade.
• Comprehensive reference list (~230 refs) and clear tables summarizing overlap (useful starting point for hypothesis generation) Review methods/summary.

Critical appraisal — limitations & blindspots

• Narrative (non-systematic) search with selection choices: risk of selection bias and no PRISMA transparency; authors excluded psychosocial-only depression papers—reasonable, but increases heterogeneity in included biomarker timing and assay methods.
• Heterogeneity across cited COVID studies (severity, timepoint, assays, variants, treatments such as steroids/IL-6 blockers) confounds inference that biomarker presence equals causal pathway for post-COVID depression; prospective baseline→outcome cohorts are required to move beyond correlation Call for prospective work.
• Lack of quantitative synthesis/meta-analysis: effect sizes and heterogeneity metrics are absent; difficult to prioritize biomarkers for clinical translation.
• Potential confounders not systematically handled: BMI, smoking, pre-existing inflammatory disease, medications (steroids, tocilizumab), vaccination status—these alter cytokines/BDNF/KYN and were often uncontrolled in cited studies.
• Reverse causality and epiphenomena risk: systemic inflammation could be general illness marker rather than depression-specific; authors acknowledge that no single biomarker is diagnostic and recommend biosignatures (appropriate).

What would strengthen/refute the paper's central claims (actionable)

1. Prospective cohort: measure baseline cytokines, KYN/TRP, BDNF and clinical scales in acute COVID-19 patients and follow for 6–12 months to test whether baseline (or early convalescent) biosignature predicts new-onset MDD (pre-specified endpoints, multivariable adjustment for confounders).
2. Standardize assays/timing: harmonize sampling windows (e.g., acute, 1 month, 3 months) and use standardized ELISA/LC-MS panels to reduce measurement heterogeneity.
3. Multimodal panels & machine learning: build and validate a multivariate biosignature (inflammatory + kynurenine + neurotrophic) with training/validation cohorts; pre-register model and cutoffs; report AUC, calibration, net reclassification index vs clinical predictors.
4. Interventional test: in biomarker-high COVID survivors, randomized immunomodulatory or neuroprotective interventions testing prevention/reduction of depressive symptoms would establish causality (ethical/feasible designs needed).

Reader checklist (practical)

• Do not treat single cytokine values as diagnostic; consider multivariate profile + clinical risk factors.
• Watch timing: acute cytokine spikes vs persistent elevation have different biological implications for neurotoxicity/priming.
• Adjust for BMI, age, sex, medications and infection severity in any secondary analyses.